The current randomized clinical trial was conducted to determine the influence of topical ketorolac combination with steroids on anterior segment inflammation and other adverse effects following phaco-surgery for pseudoexfoliation (PEX) syndrome. A total of eighty-eight patients with PEX and cataracts who had undergone phacoemulsification participated in the trial. They were randomly placed into one of two groups, which received betamethasone (0.1%) and chloramphenicol (5%) for two weeks, either with or without ketorolac eye drops (0.5%). The two groups' six-month post-operative differences in ACO (Anterior Capsule Opacification) and PCO (Posterior Capsule Opacification) were compared using SPSS 21 software. Measurements of BCVA (Best-Corrected Visual Acuity), IOP (Intraocular Pressure), and ACI (Anterior Chamber Inflammation) were taken on days 1, 3, 7, and 30 after surgery. Between the 46 patients in the study group (who took ketorolac) and the 42 patients in the control group (who did not take ketorolac), there was no change in IOP or BCVA on days 30, 7, 3, and 1 following surgery (P > 0.05). The study group had reduced levels of PCO and ACO at six months postoperatively (P